Fundz

West Pharmaceutical Services

Exton, Pennsylvania, United States · Biotechnology, Health Care, Pharmaceutical

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by deliv

Key facts

Headquarters
Exton, Pennsylvania, United States
Employees
11,000
Industries
Biotechnology, Health Care, Pharmaceutical
Status
Public (WST)
Website
westpharma.com
LinkedIn
Company page

Recent activity at West Pharmaceutical Services

  • : SEC 8-K (7.01): On October 29, 2026, West Pharmaceutical Services, Inc. filed an 8-K report under Item 7.01 to disclose information regarding its results of operations and financial condition. This includes a press release and a presentation that provides insights into the company's performance, which can be accessed through their website. The disclosure aims to provide transparency to its investors and is part of their routine financial reporting practices. This filing is crucial for stakeholders to assess the company’s financial health and strategy moving forward.
  • : SEC 8-K (1.01): On October 26, 2026, West Pharmaceutical Services, Inc. terminated its Existing Credit Agreement, originally dated March 28, 2019, after prepaying the outstanding principal amount of $130.0 million using proceeds from the newly established credit facilities. The termination was executed without incurring any early termination penalties. The new financing agreement, which includes a revolving credit facility and term loans, was also initiated on the same Effective Date, allowing the Company to utilize funds for working capital, capital expenditures, and other corporate purposes.
  • : SEC 8-K (7.01): The filing includes a Regulation FD Disclosure regarding West Pharmaceutical Services, Inc. It features a presentation and press release dated July 23, 2026, highlighting the company’s operational results and financial condition. This information will be accessible through the company's investor website and is related to the results discussed during a call. The disclosure aims to inform investors while clarifying that the information furnished is not subject to the typical liabilities of filings under the Exchange Act.
  • : SEC 8-K (7.01): On July 23, 2026, West Pharmaceutical Services, Inc. announced its second-quarter financial results, marking a significant update on its operational performance. The press release (Exhibit 99.1) details the company's financial condition, including quarterly revenue and earnings figures, which may indicate growth or changes in financial health. The information is crucial for investors and stakeholders to assess West Pharmaceutical's market position and future strategies. This report is particularly relevant as it provides fresh insights into the company's performance within the last three days, emphasizing its impact on investment decisions.
  • : West Pharmaceutical Services Enters into New Agreement with Daikyo Seiko
  • : SEC 8-K (1.01): West Pharmaceutical Services, Inc. ('the Company') has entered into a significant partnership with Daikyo Seiko, Ltd. by executing an Amended and Restated Technology Exchange and Crosslicense Agreement as well as two Distributorship Agreements, effective July 14, 2026. This collaboration strengthens their ongoing relationship, as the Company holds a 49% ownership interest in Daikyo. The new agreements largely mirror the previous arrangements from January 18, 2017, with revisions based on prior amendments. This partnership is expected to enhance their capabilities in technology exchange and distribution, impacting strategic operations significantly.
  • : SEC 8-K (1.01): West Pharmaceutical Services, Inc. has entered into an Amended and Restated Technology Exchange and Crosslicense Agreement with Daikyo Seiko, Ltd., effective July 14, 2026. The agreements facilitate joint development and shared licensing of know-how related to pharmaceutical packaging products, including closures and syringes. West holds a 49% interest in Daikyo, and the crosslicense agreement is generally royalty-free except for certain patents. Additionally, two Distributorship Agreements establish West as the exclusive distributor of Daikyo's products outside Japan and Daikyo as a non-exclusive distributor of West's products in Japan. Each agreement has a 10-year term with specific termination conditions, including mutual consent and changes in control.
  • : SEC 8-K (5.02):
  • : SEC 8-K (7.01):
  • : SEC 8-K (7.01): The filing involves a Regulation FD disclosure related to West Pharmaceutical Services, Inc. The company has incorporated information from its results of operations and financial condition into this report, including a presentation dated April 23, 2026, which will be available on their website. This disclosure aims to provide important operational updates and financial details to investors, emphasizing transparency in communications. The press release also dated April 23, 2026, relates to their financial performance and strategic outlook, crucial for shareholders and market analysts.

Leadership

  • Eric M. Green, President
  • Robert McMahon, Chief Financial Officer
  • Nilesh Shah, President

Verified email and direct lines for West Pharmaceutical Services’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

West Pharmaceutical Services files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

West Pharmaceutical Services in the news

Companies similar to West Pharmaceutical Services

About West Pharmaceutical Services: questions and answers

What does West Pharmaceutical Services do?

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by deliv

Where is West Pharmaceutical Services headquartered?

West Pharmaceutical Services is headquartered in Exton, Pennsylvania, United States.

How many employees does West Pharmaceutical Services have?

West Pharmaceutical Services has about 11,000 employees.

Who leads West Pharmaceutical Services?

Eric M. Green is a President at West Pharmaceutical Services.

What is the latest news on West Pharmaceutical Services?

On Oct 29, 2026, SEC 8-K (7.01): On October 29, 2026, West Pharmaceutical Services, Inc. filed an 8-K report under Item 7.01 to disclose information regarding its results of operations and financial condition. This includes a press release and a presentation that provides insights into the company's performance, whi

Is West Pharmaceutical Services a public company?

Yes. West Pharmaceutical Services is publicly traded under the ticker WST.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches West Pharmaceutical Services across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.